CD79A and infection: In the intermediate phase of infection (21–60 dpso), IgG and IgA antibodies against S1 of SARS‐CoV‐2 were detected in 93.3% and 82.8% of the samples (n = 31), respectively, while IgG and IgM antibodies against NCP were detected in 96.8% and 12.9%, respectively.